- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05235412
A Cohort Study on Milk Composition, Health Outcomes, and Feeding Practices of Chinese Mothers and Infants (Phoenix)
March 1, 2023 updated by: Danone Nutricia
This is a cohort study to understand the changes of breastmilk composition in the first six months after birth of Chinese infants.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The relationship of breastmilk composition, the maternal gut microbiome and lifestyle factors such as diet, feeding practices and physical activity and the infant's health and gut microbiome will be investigated in this study.
Study Type
Observational
Enrollment (Anticipated)
750
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 211166
- Recruiting
- Nanjing Medical University Jiangning Campus
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Sampling Method
Probability Sample
Study Population
Generally healthy mothers with the intention to breastfeed, and their infants.
Description
Inclusion Criteria:
Mothers:
- Generally healthy mothers with the intention to breastfeed.
- Aged 18 years and above.
- Written informed consent.
Infants:
- Generally healthy term born (gestational age between 37 and 42 weeks).
- Breastfed by their mothers, either exclusively or in combination with infant milk formula, at enrolment.
- Chinese ethnicity of mother and father.
Exclusion Criteria:
Mothers:
- Participation in any other studies involving investigational or marketed products concomitantly or two weeks prior to entry into the study.
- Difficulty to follow up and/or locate (e.g. known transfer to other hospitals, residing outside the city where the study site is located, or planning to move out of the current city; incapability of mothers to comply with study protocol or investigator' s uncertainty about the willingness or ability of the mothers to understand and comply with the protocol requirements.
- Illegal drug use.
- Regular smoking and/ or consumption of alcoholic beverages as per investigator's judgement.
- A BMI of <18.5 or ≥ 28 pre-pregnancy or during the first regular pregnancy check around or before 16 weeks of gestational age.
- Acute infectious disease or neoplastic disease or any kind of weakening or debilitating conditions (with history of positive, hepatitis C virus (HCV) or HIV serological test at any time during the pregnancy).
- Presence of mastitis, fungal infections of the nipple or areola; reactivation of herpes simplex (HSV) or varicella zoster infection in the mammary or thoracic region at the time of enrolment.
- Presence of chronic diseases such as endocrine, cardiovascular, renal, respiratory or hepatic diseases.
- Presence of psychosis and severe post-partum depression.
- Presence of autoimmune disease such as systemic lupus erythematosus, systemic scleroderma, ulcerative colitis, Crohn's disease, celiac disease.
- Women whose health condition, according to the investigator's judgement, could interfere with the study conduction and assessment.
- Mothers who have given birth to twins or multiples or infant conceived with Assisted Reproductive Technology (ART).
Infants:
- Participation in any other studies involving investigational or marketed products concomitantly or two weeks prior to entry into the study.
- At enrolment, any congenital abnormality, chromosomal disorder or severe disease which could interfere with the study conduct and assessment.
- Consumption of food other than breast milk or infant formula.
- Fully formula fed at enrolment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Chinese mothers with the intention to breastfeed, and their infants.
Observational study.
|
Exposures of interest: Maternal diet and lifestyle, demographics, anthropometrics, infant's health outcomes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in human milk protein concentration
Time Frame: Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Protein concentration in g/l of human milk will be analyzed
|
Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Changes in human milk fat concentration
Time Frame: Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Fat concentration in g/l of human milk will be analyzed
|
Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Changes in human milk carbohydrate concentration
Time Frame: Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Carbohydrate concentration in g/l of human milk will be analyzed
|
Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Changes in human milk energy content
Time Frame: Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Energy content in kCal/l of human milk will be analyzed
|
Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Changes in infant length
Time Frame: Anthropometrics collected at birth, and 1 month, 3 month, 6 months, 12 months after infant birth
|
Length measured in cm
|
Anthropometrics collected at birth, and 1 month, 3 month, 6 months, 12 months after infant birth
|
Changes in infant head circumference
Time Frame: Anthropometrics collected at birth, and 1 month, 3 month, 6 months, 12 months after infant birth
|
Head circumference measured in cm
|
Anthropometrics collected at birth, and 1 month, 3 month, 6 months, 12 months after infant birth
|
Changes in infant weight
Time Frame: Anthropometrics collected at birth, and 1 month, 3 month, 6 months, 12 months after infant birth
|
Weight measured in grams
|
Anthropometrics collected at birth, and 1 month, 3 month, 6 months, 12 months after infant birth
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Variations in human milk microbiome
Time Frame: Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Analyzed by sequencing
|
Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Variations in human milk micronutrients
Time Frame: Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Analyzed by mass spectrometry
|
Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Variations in human milk oligosaccharides (HMOs)
Time Frame: Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Analyzed by mass spectrometry
|
Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Variations in human milk lipid composition
Time Frame: Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Analyzed by mass spectrometry
|
Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Variations in human milk amino acids and proteins
Time Frame: Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Analyzed by mass spectrometry
|
Human milk samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Variations in infant fecal microbiome
Time Frame: Infant fecal samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Analyzed by sequencing
|
Infant fecal samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Variations in maternal fecal microbiome
Time Frame: Maternal fecal samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Analyzed by sequencing
|
Maternal fecal samples collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Changes in infant stool consistency and frequency
Time Frame: Data collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Data will be collected via diaries using the Brussel Infant and Toddler Stool Scale
|
Data collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Changes in infant feeding practices
Time Frame: Data collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Dietary data will be collected via questionnaires
|
Data collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Changes in maternal body mass index
Time Frame: Data collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Maternal weight and height will be combined to determine body mass index [kg/m2]
|
Data collected at 1 month, 3 month, 6 months, 12 months after infant birth
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 19, 2021
Primary Completion (Anticipated)
November 30, 2024
Study Completion (Anticipated)
March 30, 2025
Study Registration Dates
First Submitted
December 10, 2021
First Submitted That Met QC Criteria
February 8, 2022
First Posted (Actual)
February 11, 2022
Study Record Updates
Last Update Posted (Actual)
March 2, 2023
Last Update Submitted That Met QC Criteria
March 1, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- SBB20R&32016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Feeding
-
London School of Hygiene and Tropical MedicineFHI 360; AFRICSanté; Centre MurazCompleted
-
Sakarya UniversityNot yet recruitingBreast Feeding | Feeding BehaviorTurkey
-
Selcuk UniversityRecruitingHospitalization | Feeding Patterns | Breast Feeding, ExclusiveTurkey
-
Taipei Medical UniversityCompletedBreast Feeding | Self Efficacy | Feeding BehaviorIndonesia
-
University Hospitals Cleveland Medical CenterNot yet recruiting
-
TC Erciyes UniversityRecruiting
-
Eskisehir Osmangazi UniversityRecruiting
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
OhioHealthClaremont McKenna College; Denison UniversityCompletedBreast FeedingUnited States
Clinical Trials on Not applicable: Observational study without any interventions.
-
Charite University, Berlin, GermanyRecruiting
-
Charite University, Berlin, GermanySanofi; LEO PharmaRecruitingAtopic DermatitisGermany
-
University College, LondonCompletedIron Deficiency | Anaemia | Cardiac Patients | Vascular Patients
-
Kang Stem Biotech Co., Ltd.Active, not recruitingAtopic DermatitisKorea, Republic of
-
Charite University, Berlin, GermanyRecruitingAnaphylaxisGermany
-
Children's Hospital of Fudan UniversityNot yet recruitingChild | Injuries
-
Kang Stem Biotech Co., Ltd.RecruitingRheumatoid ArthritisKorea, Republic of
-
AmgenCompletedAcute Lymphoblastic LeukemiaUnited States, Czechia, Spain, France, Italy, Germany, United Kingdom, Poland
-
Azienda Ospedaliera Universitaria Integrata VeronaCompleted
-
AmgenTerminatedLow Birth Weight | Birth Defect | Spontaneous Abortions